Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction

Patients with heart failure with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and it is not known if supplementing with ubiquinol and/or D-ribose could improve outcomes. The overall objective of this study was to determine if ubiquinol and/ or D-ribose would reduce the symptoms and improve cardiac performance in patients with HFpEF. This was a phase 2 randomized, double-blind, placebo-controlled trial of 216 patients with HFpEF who were >= 50 years old with a left ventricular ejection fraction (EF) >= 50%. A total of 4 study groups received various supplements over 12 weeks: Group 1 received placebo ubiquinol capsules and D-ribose powder, Group 2 received ubiquinol capsules (600 mg/d) and placebo D-ribose powder, Group 3 received placebo ubiquinol capsules with D-ribose powder (15 g/d), and Group 4 received ubiquinol capsules and D ribose powder. There were 7 outcome measures for this study: Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, level of vigor using a subscale from the Profile of Mood States, EF, the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (septal E/e' ratio), B-type natriuretic peptides, lactate/adenosine triphosphate ratio, and the 6-minute walk test. Treatment with ubiquinol and/or D ribose significantly improved the KCCQ clinical summary score (17.30 to 25.82 points), vigor score (7.65 to 8.15 points), and EF (7.08% to 8.03%) and reduced B-type natriuretic peptides (-72.02 to -47.51) and lactate/adenosine triphosphate ratio (-4.32 to -3.35 x 10(-4)). There were no significant increases in the septal E/e0 or the 6-minute walk test. In conclusion, ubiquinol and D-ribose reduced the symptoms of HFpEF and increased the EF. These findings support the use of these supplements in addition to standard therapeutic treatments for patients with HFpEF. (C) 2022 Elsevier Inc. All rights reserved.